Weichert W - Search Results

1

New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma.

Golob-Schwarzl N, Puchas P, Gogg-Kamerer M, Weichert W, Göppert B, Haybaeck J. Golob-Schwarzl N, et al. Among authors: weichert w. Anticancer Res. 2020 Jun;40(6):3109-3118. doi: 10.21873/anticanres.14292. Anticancer Res. 2020. PMID: 32487605

2

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.

Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A, Kamphues C, Dietel M, Riess H. Sinn BV, et al. Among authors: weichert w. Pancreas. 2014 May;43(4):578-83. doi: 10.1097/MPA.0000000000000077. Pancreas. 2014. PMID: 24681874

3

MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases.

Gonçalves JPL, Bollwein C, Schlitter AM, Kriegsmann M, Jacob A, Weichert W, Schwamborn K. Gonçalves JPL, et al. Among authors: weichert w. Molecules. 2022 Jul 27;27(15):4811. doi: 10.3390/molecules27154811. Molecules. 2022. PMID: 35956764 Free PMC article.

4

Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.

Riener MO, Pilarsky C, Gerhardt J, Grützmann R, Fritzsche FR, Bahra M, Weichert W, Kristiansen G. Riener MO, et al. Among authors: weichert w. Histol Histopathol. 2009 Sep;24(9):1121-8. doi: 10.14670/HH-24.1121. Histol Histopathol. 2009. PMID: 19609859

5

High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer.

Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C, Weichert W, Dietel M, Rabien A, Klauschen F. Stenzinger A, et al. Among authors: weichert w. Hum Pathol. 2012 Sep;43(9):1471-81. doi: 10.1016/j.humpath.2011.10.023. Epub 2012 Mar 12. Hum Pathol. 2012. PMID: 22417846

6

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.

Stenzinger A, Endris V, Klauschen F, Sinn B, Lorenz K, Warth A, Goeppert B, Ehemann V, Muckenhuber A, Kamphues C, Bahra M, Neuhaus P, Weichert W. Stenzinger A, et al. Among authors: weichert w. BMC Cancer. 2013 Oct 2;13:450. doi: 10.1186/1471-2407-13-450. BMC Cancer. 2013. PMID: 24088390 Free PMC article.

7

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D. Goeppert B, et al. Among authors: weichert w. Mod Pathol. 2014 Jul;27(7):1028-34. doi: 10.1038/modpathol.2013.206. Epub 2013 Dec 6. Mod Pathol. 2014. PMID: 24309328 Free article.

8

ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.

Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, Schirmacher P, Penzel R, Weichert W. Warth A, et al. Among authors: weichert w. Histopathology. 2014 Aug;65(2):187-94. doi: 10.1111/his.12379. Epub 2014 Apr 3. Histopathology. 2014. PMID: 24456475

9

Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.

Kamphues C, Bova R, Bahra M, Klauschen F, Muckenhuber A, Sinn BV, Warth A, Goeppert B, Endris V, Neuhaus P, Weichert W, Stenzinger A. Kamphues C, et al. Among authors: weichert w. Pancreas. 2015 Mar;44(2):296-301. doi: 10.1097/MPA.0000000000000248. Pancreas. 2015. PMID: 25423555

10

CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma.

Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aykut B, Mateos A, Herhaus P, Sancho-Martinez I, Hill O, Gieffers C, Sykora J, Weichert W, Eisen C, Trumpp A, Sprick MR, Bergmann F, Welsch T, Martin-Villalba A. Teodorczyk M, et al. Among authors: weichert w. Cell Death Differ. 2015 Jul;22(7):1192-202. doi: 10.1038/cdd.2014.217. Epub 2015 Jan 23. Cell Death Differ. 2015. PMID: 25613377 Free PMC article.

11

Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.

Muckenhuber A, Berger AK, Schlitter AM, Steiger K, Konukiewitz B, Trumpp A, Eils R, Werner J, Friess H, Esposito I, Klöppel G, Ceyhan GO, Jesinghaus M, Denkert C, Bahra M, Stenzinger A, Sprick MR, Jäger D, Springfeld C, Weichert W. Muckenhuber A, et al. Among authors: weichert w. Clin Cancer Res. 2018 Jan 15;24(2):351-359. doi: 10.1158/1078-0432.CCR-17-2180. Epub 2017 Nov 3. Clin Cancer Res. 2018. PMID: 29101303

12

MTOR inhibitor-based combination therapies for pancreatic cancer.

Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B, Ceyhan GO, Knauer SK, Weichert W, Schmid RM, Stauber R, Arlt A, Krämer OH, Rad R, Reichert M, Saur D, Schneider G. Hassan Z, et al. Among authors: weichert w. Br J Cancer. 2018 Feb 6;118(3):366-377. doi: 10.1038/bjc.2017.421. Epub 2018 Jan 2. Br J Cancer. 2018. PMID: 29384525 Free PMC article.

13

Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration.

Kaissis GA, Lohöfer FK, Ziegelmayer S, Danner J, Jäger C, Schirren R, Ankerst D, Ceyhan GO, Friess H, Rummeny EJ, Weichert W, Braren RF. Kaissis GA, et al. Among authors: weichert w. PLoS One. 2019 Jan 2;14(1):e0208717. doi: 10.1371/journal.pone.0208717. eCollection 2019. PLoS One. 2019. PMID: 30601813 Free PMC article.

14

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.

Kaissis G, Ziegelmayer S, Lohöfer F, Steiger K, Algül H, Muckenhuber A, Yen HY, Rummeny E, Friess H, Schmid R, Weichert W, Siveke JT, Braren R. Kaissis G, et al. Among authors: weichert w. PLoS One. 2019 Oct 2;14(10):e0218642. doi: 10.1371/journal.pone.0218642. eCollection 2019. PLoS One. 2019. PMID: 31577805 Free PMC article.

15

A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging.

Kaissis G, Ziegelmayer S, Lohöfer F, Algül H, Eiber M, Weichert W, Schmid R, Friess H, Rummeny E, Ankerst D, Siveke J, Braren R. Kaissis G, et al. Among authors: weichert w. Eur Radiol Exp. 2019 Oct 17;3(1):41. doi: 10.1186/s41747-019-0119-0. Eur Radiol Exp. 2019. PMID: 31624935 Free PMC article.

16

Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma.

Kaissis GA, Ziegelmayer S, Lohöfer FK, Harder FN, Jungmann F, Sasse D, Muckenhuber A, Yen HY, Steiger K, Siveke J, Friess H, Schmid R, Weichert W, Makowski MR, Braren RF. Kaissis GA, et al. Among authors: weichert w. J Clin Med. 2020 Mar 7;9(3):724. doi: 10.3390/jcm9030724. J Clin Med. 2020. PMID: 32155990 Free PMC article.

17

Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.

Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Jiang H, et al. Among authors: weichert w. J Clin Invest. 2020 Sep 1;130(9):4704-4709. doi: 10.1172/JCI136760. J Clin Invest. 2020. PMID: 32749238 Free PMC article.

18

Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems.

Peschke K, Jakubowsky H, Schäfer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, Öllinger R, Steiger K, Schlitter M, Weichert W, Mayr U, Phillip V, Schlag C, Schmid RM, Braren RF, Kong B, Demir IE, Friess H, Rad R, Saur D, Schneider G, Reichert M. Peschke K, et al. Among authors: weichert w. EMBO Mol Med. 2022 Apr 7;14(4):e14876. doi: 10.15252/emmm.202114876. Epub 2022 Feb 4. EMBO Mol Med. 2022. PMID: 35119792 Free PMC article.

19

Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.

Mikuteit M, Steffens S, Zschäbitz S, Autenrieth M, Weichert W, Hartmann A, Erlmeier F. Mikuteit M, et al. Among authors: weichert w. Oncology. 2022;100(6):331-336. doi: 10.1159/000522592. Epub 2022 Feb 15. Oncology. 2022. PMID: 35168242

20

Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.

Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, Bahra M, Denkert C, Dietel M, Kristiansen G. Weichert W, et al. Pancreatology. 2005;5(2-3):259-65. doi: 10.1159/000085280. Epub 2005 Apr 22. Pancreatology. 2005. PMID: 15855824

21

Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Noske A, Weichert W, Buckendahl AC, Budczies J, Müller BM, Elwali NE, Dietel M, Denkert C. Faggad A, et al. Among authors: weichert w. Histopathology. 2009 May;54(6):657-66. doi: 10.1111/j.1365-2559.2009.03297.x. Histopathology. 2009. PMID: 19438741

22

Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.

Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Müller BM, Wirtz R, Chekerov R, Weichert W, Sinn B, Mucha C, Elwali NE, Schäfer R, Dietel M, Denkert C. Faggad A, et al. Among authors: weichert w. J Pathol. 2010 Feb;220(3):382-91. doi: 10.1002/path.2658. J Pathol. 2010. PMID: 19960504

23

Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.

Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Andrulis M, et al. Among authors: weichert w. Am J Surg Pathol. 2012 Dec;36(12):1796-800. doi: 10.1097/PAS.0b013e3182549b50. Am J Surg Pathol. 2012. PMID: 22531170

24

Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.

Goeppert B, Konermann C, Schmidt CR, Bogatyrova O, Geiselhart L, Ernst C, Gu L, Becker N, Zucknick M, Mehrabi A, Hafezi M, Klauschen F, Stenzinger A, Warth A, Breuhahn K, Renner M, Weichert W, Schirmacher P, Plass C, Weichenhan D. Goeppert B, et al. Among authors: weichert w. Hepatology. 2014 Feb;59(2):544-54. doi: 10.1002/hep.26721. Epub 2013 Dec 24. Hepatology. 2014. PMID: 24002901

25

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R, Böhm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S. Göke F, et al. Among authors: weichert w. Digestion. 2013;88(3):172-81. doi: 10.1159/000355018. Epub 2013 Oct 17. Digestion. 2013. PMID: 24135816 Free PMC article.

26

Preanalytics in lung cancer.

Warth A, Muley T, Meister M, Weichert W. Warth A, et al. Among authors: weichert w. Recent Results Cancer Res. 2015;199:71-84. doi: 10.1007/978-3-319-13957-9_8. Recent Results Cancer Res. 2015. PMID: 25636431 Review.

27

Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed.

Muckenhuber A, Babitzki G, Thomas M, Hölzlwimmer G, Zajac M, Jesinghaus M, Bergmann F, Werner J, Stenzinger A, Weichert W. Muckenhuber A, et al. Among authors: weichert w. Pancreas. 2016 Sep;45(8):1167-74. doi: 10.1097/MPA.0000000000000604. Pancreas. 2016. PMID: 26825865

28

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. Noll EM, et al. Among authors: weichert w. Nat Med. 2016 Mar;22(3):278-87. doi: 10.1038/nm.4038. Epub 2016 Feb 8. Nat Med. 2016. PMID: 26855150 Free PMC article.

29

A new classification method for MALDI imaging mass spectrometry data acquired on formalin-fixed paraffin-embedded tissue samples.

Boskamp T, Lachmund D, Oetjen J, Cordero Hernandez Y, Trede D, Maass P, Casadonte R, Kriegsmann J, Warth A, Dienemann H, Weichert W, Kriegsmann M. Boskamp T, et al. Among authors: weichert w. Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):916-926. doi: 10.1016/j.bbapap.2016.11.003. Epub 2016 Nov 9. Biochim Biophys Acta Proteins Proteom. 2017. PMID: 27836618

30

PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S. Erlmeier F, et al. Among authors: weichert w. Med Oncol. 2017 May;34(5):71. doi: 10.1007/s12032-017-0926-1. Epub 2017 Mar 28. Med Oncol. 2017. PMID: 28353093

31

Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions.

Steiger K, Schlitter AM, Weichert W, Esposito I, Wester HJ, Notni J. Steiger K, et al. Among authors: weichert w. Mol Imaging. 2017 Jan 1;16:1536012117709384. doi: 10.1177/1536012117709384. Mol Imaging. 2017. PMID: 28627323 Free PMC article.

32

pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma.

Schlitter AM, Jesinghaus M, Jäger C, Konukiewitz B, Muckenhuber A, Demir IE, Bahra M, Denkert C, Friess H, Kloeppel G, Ceyhan GO, Weichert W. Schlitter AM, et al. Among authors: weichert w. Eur J Cancer. 2017 Oct;84:121-129. doi: 10.1016/j.ejca.2017.06.034. Epub 2017 Aug 10. Eur J Cancer. 2017. PMID: 28802189

33

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H. Heining C, et al. Among authors: weichert w. Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25. Cancer Discov. 2018. PMID: 29802158

34

Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice.

Görgülü K, Diakopoulos KN, Ai J, Schoeps B, Kabacaoglu D, Karpathaki AF, Ciecielski KJ, Kaya-Aksoy E, Ruess DA, Berninger A, Kowalska M, Stevanovic M, Wörmann SM, Wartmann T, Zhao Y, Halangk W, Voronina S, Tepikin A, Schlitter AM, Steiger K, Artati A, Adamski J, Aichler M, Walch A, Jastroch M, Hartleben G, Mantzoros CS, Weichert W, Schmid RM, Herzig S, Krüger A, Sainz B Jr, Lesina M, Algül H. Görgülü K, et al. Among authors: weichert w. Gastroenterology. 2019 Jan;156(1):203-217.e20. doi: 10.1053/j.gastro.2018.09.053. Epub 2018 Oct 6. Gastroenterology. 2019. PMID: 30296435

35

Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations.

Kazdal D, Harms A, Endris V, Penzel R, Oliveira C, Kriegsmann M, Longuespée R, Winter H, Schneider MA, Muley T, Pfarr N, Weichert W, Stenzinger A, Warth A. Kazdal D, et al. Among authors: weichert w. Lung Cancer. 2018 Dec;126:80-88. doi: 10.1016/j.lungcan.2018.10.024. Epub 2018 Oct 29. Lung Cancer. 2018. PMID: 30527196

36

Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.

Pfarr N, Allgäuer M, Steiger K, Weichert W, Schirmacher P, Noske A, Stenzinger A. Pfarr N, et al. Among authors: weichert w. Pathology. 2019 Jun;51(4):362-368. doi: 10.1016/j.pathol.2019.01.010. Epub 2019 Apr 19. Pathology. 2019. PMID: 31010589

37

Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.

Mota Reyes C, Teller S, Muckenhuber A, Konukiewitz B, Safak O, Weichert W, Friess H, Ceyhan GO, Demir IE. Mota Reyes C, et al. Among authors: weichert w. Clin Cancer Res. 2020 Jan 1;26(1):220-231. doi: 10.1158/1078-0432.CCR-19-1864. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585935

38

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.

Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. Biederstädt A, et al. Among authors: weichert w. Gut. 2020 Aug;69(8):1472-1482. doi: 10.1136/gutjnl-2018-317856. Epub 2020 Jan 30. Gut. 2020. PMID: 32001555 Free PMC article.

39

Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters.

Kaissis GA, Jungmann F, Ziegelmayer S, Lohöfer FK, Harder FN, Schlitter AM, Muckenhuber A, Steiger K, Schirren R, Friess H, Schmid R, Weichert W, Makowski MR, Braren RF. Kaissis GA, et al. Among authors: weichert w. J Clin Med. 2020 Apr 25;9(5):1250. doi: 10.3390/jcm9051250. J Clin Med. 2020. PMID: 32344944 Free PMC article.

40

Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.

Kriegsmann K, Flechtenmacher C, Heil J, Kriegsmann J, Mechtersheimer G, Aulmann S, Weichert W, Sinn HP, Kriegsmann M. Kriegsmann K, et al. Among authors: weichert w. Int J Mol Sci. 2020 Sep 3;21(17):6407. doi: 10.3390/ijms21176407. Int J Mol Sci. 2020. PMID: 32899175 Free PMC article.

41

Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.

Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, Engleitner T, Öllinger R, Nomura A, Wirges N, Papargyriou A, Jahan Sarker RS, Ranjan RA, Dantes Z, Weichert W, Rustgi AK, Schmid RM, Rad R, Schneider G, Saur D, Reichert M. Feldmann K, et al. Among authors: weichert w. Gastroenterology. 2021 Jan;160(1):346-361.e24. doi: 10.1053/j.gastro.2020.09.010. Epub 2020 Sep 30. Gastroenterology. 2021. PMID: 33007300 Free article.

42

Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin.

Espinet E, Gu Z, Imbusch CD, Giese NA, Büscher M, Safavi M, Weisenburger S, Klein C, Vogel V, Falcone M, Insua-Rodríguez J, Reitberger M, Thiel V, Kossi SO, Muckenhuber A, Sarai K, Lee AYL, Backx E, Zarei S, Gaida MM, Rodríguez-Paredes M, Donato E, Yen HY, Eils R, Schlesner M, Pfarr N, Hackert T, Plass C, Brors B, Steiger K, Weichenhan D, Arda HE, Rooman I, Kopp JL, Strobel O, Weichert W, Sprick MR, Trumpp A. Espinet E, et al. Among authors: weichert w. Cancer Discov. 2021 Mar;11(3):638-659. doi: 10.1158/2159-8290.CD-20-1202. Epub 2020 Oct 15. Cancer Discov. 2021. PMID: 33060108 Free PMC article.

43

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma.

Sun N, Trajkovic-Arsic M, Li F, Wu Y, Münch C, Kunzke T, Feuchtinger A, Steiger K, Schlitter AM, Weichert W, Esposito I, Siveke JT, Walch A. Sun N, et al. Among authors: weichert w. EJNMMI Res. 2021 Dec 1;11(1):120. doi: 10.1186/s13550-021-00862-y. EJNMMI Res. 2021. PMID: 34851463 Free PMC article.

44

MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.

Bollwein C, Gonҫalves JPL, Utpatel K, Weichert W, Schwamborn K. Bollwein C, et al. Among authors: weichert w. Molecules. 2022 May 27;27(11):3464. doi: 10.3390/molecules27113464. Molecules. 2022. PMID: 35684402 Free PMC article.

45

Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.

Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Röske A, Sehouli J, Dietel M, Denkert C. Noske A, et al. Among authors: weichert w. Oncol Rep. 2008 Dec;20(6):1409-17. Oncol Rep. 2008. PMID: 19020722

46

Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression.

Tchernitsa O, Kasajima A, Schäfer R, Kuban RJ, Ungethüm U, Györffy B, Neumann U, Simon E, Weichert W, Ebert MP, Röcken C. Tchernitsa O, et al. Among authors: weichert w. J Pathol. 2010 Nov;222(3):310-9. doi: 10.1002/path.2759. J Pathol. 2010. PMID: 20726036

47

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Röcken C, Wiedenmann B, Weichert W. Kasajima A, et al. Among authors: weichert w. Endocr Relat Cancer. 2011 Jan 13;18(1):181-92. doi: 10.1677/ERC-10-0126. Print 2011 Feb. Endocr Relat Cancer. 2011. PMID: 21159731

48

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.

Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA, Schirmacher P, Hoffmann H, Muley T, Weichert W. Warth A, et al. Among authors: weichert w. Eur Respir J. 2014 Mar;43(3):872-83. doi: 10.1183/09031936.00018013. Epub 2013 Aug 29. Eur Respir J. 2014. PMID: 23988776 Free article.

49

RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma.

Hassel JC, Groesser L, Herschberger E, Weichert W, Hafner C. Hassel JC, et al. Among authors: weichert w. J Invest Dermatol. 2015 Feb;135(2):636-639. doi: 10.1038/jid.2014.360. Epub 2014 Jul 18. J Invest Dermatol. 2015. PMID: 25118623 Free article. No abstract available.

50

Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma.

Freudlsperger C, Horn D, Weißfuß S, Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert P, Hoffmann J, Freier K, Hess J. Freudlsperger C, et al. Among authors: weichert w. Int J Cancer. 2015 Jun 15;136(12):2775-85. doi: 10.1002/ijc.29328. Epub 2014 Nov 26. Int J Cancer. 2015. PMID: 25388642 Free article.

51

Clinical Relevance of Different Papillary Growth Patterns of Pulmonary Adenocarcinoma.

Warth A, Muley T, Harms A, Hoffmann H, Dienemann H, Schirmacher P, Weichert W. Warth A, et al. Among authors: weichert w. Am J Surg Pathol. 2016 Jun;40(6):818-26. doi: 10.1097/PAS.0000000000000622. Am J Surg Pathol. 2016. PMID: 26927890

52

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R. Scheel AH, et al. Among authors: weichert w. Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8. Mod Pathol. 2016. PMID: 27389313 Free article.

53

Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.

Volckmar AL, Leichsenring J, Flechtenmacher C, Pfarr N, Siebolts U, Kirchner M, Budczies J, Bockmayr M, Ridinger K, Lorenz K, Herpel E, Noske A, Weichert W, Klauschen F, Schirmacher P, Penzel R, Endris V, Stenzinger A. Volckmar AL, et al. Among authors: weichert w. Genes Chromosomes Cancer. 2017 Jan;56(1):11-17. doi: 10.1002/gcc.22396. Epub 2016 Aug 9. Genes Chromosomes Cancer. 2017. PMID: 27438523

54

Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.

Kriegsmann M, Casadonte R, Kriegsmann J, Dienemann H, Schirmacher P, Hendrik Kobarg J, Schwamborn K, Stenzinger A, Warth A, Weichert W. Kriegsmann M, et al. Among authors: weichert w. Mol Cell Proteomics. 2016 Oct;15(10):3081-3089. doi: 10.1074/mcp.M115.057513. Epub 2016 Jul 29. Mol Cell Proteomics. 2016. PMID: 27473201 Free PMC article.

55

Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.

Goeppert B, Ernst C, Baer C, Roessler S, Renner M, Mehrabi A, Hafezi M, Pathil A, Warth A, Stenzinger A, Weichert W, Bähr M, Will R, Schirmacher P, Plass C, Weichenhan D. Goeppert B, et al. Among authors: weichert w. Epigenetics. 2016 Nov;11(11):780-790. doi: 10.1080/15592294.2016.1227899. Epub 2016 Sep 3. Epigenetics. 2016. PMID: 27593557 Free PMC article.

56

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.

Kazdal D, Harms A, Endris V, Penzel R, Kriegsmann M, Eichhorn F, Muley T, Stenzinger A, Pfarr N, Weichert W, Warth A. Kazdal D, et al. Among authors: weichert w. Br J Cancer. 2017 Jul 11;117(2):220-226. doi: 10.1038/bjc.2017.155. Epub 2017 May 30. Br J Cancer. 2017. PMID: 28557978 Free PMC article.

57

Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.

Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M. Jesinghaus M, et al. Among authors: weichert w. Oncotarget. 2017 Jul 18;8(29):46756-46768. doi: 10.18632/oncotarget.18606. Oncotarget. 2017. PMID: 28657901 Free PMC article.

58

Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Geng X, Liu Y, Diersch S, Kotzsch M, Grill S, Weichert W, Kiechle M, Magdolen V, Dorn J. Geng X, et al. Among authors: weichert w. PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017. PLoS One. 2017. PMID: 29095848 Free PMC article.

59

Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3.

Konukiewitz B, Jesinghaus M, Steiger K, Schlitter AM, Kasajima A, Sipos B, Zamboni G, Weichert W, Pfarr N, Klöppel G. Konukiewitz B, et al. Among authors: weichert w. Hum Pathol. 2018 Jul;77:70-79. doi: 10.1016/j.humpath.2018.03.018. Epub 2018 Mar 26. Hum Pathol. 2018. PMID: 29596894

60

Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer.

Bormann F, Stinzing S, Tierling S, Morkel M, Markelova MR, Walter J, Weichert W, Roßner F, Kuhn N, Perner J, Dietz J, Ispasanie S, Dietel M, Schäfer R, Heinemann V, Sers C. Bormann F, et al. Among authors: weichert w. Int J Cancer. 2019 Feb 1;144(3):569-581. doi: 10.1002/ijc.31892. Epub 2018 Nov 7. Int J Cancer. 2019. PMID: 30252132 Free article.

61

Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20.

Kasajima A, Konukiewitz B, Oka N, Suzuki H, Sakurada A, Okada Y, Kameya T, Ishikawa Y, Sasano H, Weichert W, Klöppel G. Kasajima A, et al. Among authors: weichert w. Neuroendocrinology. 2019;108(2):109-120. doi: 10.1159/000495806. Epub 2018 Nov 28. Neuroendocrinology. 2019. PMID: 30485860

62

Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control.

Mogler C, Koschny R, Heilig CE, Frohling S, Schirmacher P, Weichert W, Pfarr N. Mogler C, et al. Among authors: weichert w. Genes Chromosomes Cancer. 2020 Feb;59(2):106-110. doi: 10.1002/gcc.22795. Epub 2019 Sep 3. Genes Chromosomes Cancer. 2020. PMID: 31390105

63

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.

Badr M, Jöhrens K, Allgäuer M, Boxberg M, Weichert W, Tinhofer I, Denkert C, Schirmacher P, Stenzinger A, Budczies J. Badr M, et al. Among authors: weichert w. Cancer Immunol Immunother. 2019 Sep;68(9):1443-1454. doi: 10.1007/s00262-019-02378-w. Epub 2019 Aug 23. Cancer Immunol Immunother. 2019. PMID: 31444607 Free PMC article.

64

PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer.

Liotta L, Lange S, Maurer HC, Olive KP, Braren R, Pfarr N, Burger S, Muckenhuber A, Jesinghaus M, Steiger K, Weichert W, Friess H, Schmid R, Algül H, Jost PJ, Ramser J, Fischer C, Quante AS, Reichert M, Quante M. Liotta L, et al. Among authors: weichert w. JCI Insight. 2021 Mar 25;6(8):e141532. doi: 10.1172/jci.insight.141532. JCI Insight. 2021. PMID: 33764904 Free PMC article.

65

[¹⁸F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma.

Harder FN, Jungmann F, Kaissis GA, Lohöfer FK, Ziegelmayer S, Havel D, Quante M, Reichert M, Schmid RM, Demir IE, Friess H, Wildgruber M, Siveke J, Muckenhuber A, Steiger K, Weichert W, Rauscher I, Eiber M, Makowski MR, Braren RF. Harder FN, et al. Among authors: weichert w. EJNMMI Res. 2021 Jul 28;11(1):70. doi: 10.1186/s13550-021-00808-4. EJNMMI Res. 2021. PMID: 34322781 Free PMC article.

66

Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.

Mikuteit M, Zschäbitz S, Erlmeier M, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F. Mikuteit M, et al. Among authors: weichert w. Oncology. 2022;100(10):536-541. doi: 10.1159/000525601. Epub 2022 Jun 27. Oncology. 2022. PMID: 35760058 Free PMC article.

67

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.

de Andrés MP, Jackson RJ, Felipe I, Zagorac S, Pilarsky C, Schlitter AM, Martinez de Villareal J, Jang GH, Costello E, Gallinger S, Ghaneh P, Greenhalf W, Knösel T, Palmer DH, Ruemmele P, Weichert W, Buechler M, Hackert T, Neoptolemos JP, Notta F, Malats N, Martinelli P, Real FX. de Andrés MP, et al. Among authors: weichert w. Gut. 2023 Mar;72(3):535-548. doi: 10.1136/gutjnl-2021-325803. Epub 2022 Sep 15. Gut. 2023. PMID: 36109153

68

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping.

Lautizi M, Baumbach J, Weichert W, Steiger K, List M, Pfarr N, Kacprowski T. Lautizi M, et al. Among authors: weichert w. NAR Cancer. 2022 Oct 17;4(4):zcac030. doi: 10.1093/narcan/zcac030. eCollection 2022 Dec. NAR Cancer. 2022. PMID: 36267208 Free PMC article.

69

Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.

Erlmeier M, Mikuteit M, Zschäbitz S, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F. Erlmeier M, et al. Among authors: weichert w. BMC Urol. 2023 May 11;23(1):90. doi: 10.1186/s12894-023-01263-0. BMC Urol. 2023. PMID: 37170275 Free PMC article.

70

Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.

Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. Weichert W, et al. Prostate. 2004 Aug 1;60(3):240-5. doi: 10.1002/pros.20050. Prostate. 2004. PMID: 15176053

71

Polo-like kinase 1 expression is a prognostic factor in human colon cancer.

Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, Dietel M, Denkert C. Weichert W, et al. World J Gastroenterol. 2005 Sep 28;11(36):5644-50. doi: 10.3748/wjg.v11.i36.5644. World J Gastroenterol. 2005. PMID: 16237758 Free PMC article.

72

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.

Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M, Denkert C. Darb-Esfahani S, et al. Among authors: weichert w. J Cancer Res Clin Oncol. 2009 Jul;135(7):933-41. doi: 10.1007/s00432-008-0529-5. Epub 2008 Dec 24. J Cancer Res Clin Oncol. 2009. PMID: 19107520

73

Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.

Warth A, Muley T, Herpel E, Meister M, Herth FJ, Schirmacher P, Weichert W, Hoffmann H, Schnabel PA. Warth A, et al. Among authors: weichert w. Histopathology. 2012 Dec;61(6):1017-25. doi: 10.1111/j.1365-2559.2012.04308.x. Epub 2012 Aug 8. Histopathology. 2012. PMID: 22882703

74

Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma.

Weichert W, Warth A. Weichert W, et al. Curr Opin Pulm Med. 2014 Jul;20(4):309-16. doi: 10.1097/MCP.0000000000000065. Curr Opin Pulm Med. 2014. PMID: 24811831 Review.

75

Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.

Stenzinger A, Pfarr N, Endris V, Penzel R, Jansen L, Wolf T, Herpel E, Warth A, Klauschen F, Kloor M, Roth W, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M, Weichert W. Stenzinger A, et al. Among authors: weichert w. Cancer Med. 2014 Dec;3(6):1527-38. doi: 10.1002/cam4.305. Epub 2014 Aug 1. Cancer Med. 2014. PMID: 25124163 Free PMC article.

76

Angiogenic and growth factors in gastric cancer.

Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, Schmidt T, Ott K. Blank S, et al. Among authors: weichert w. J Surg Res. 2015 Apr;194(2):420-429. doi: 10.1016/j.jss.2014.11.028. Epub 2014 Nov 26. J Surg Res. 2015. PMID: 25577146

77

NUT carcinoma of the thorax: Case report and review of the literature.

Harms A, Herpel E, Pfarr N, Penzel R, Heussel CP, Herth FJ, Dienemann H, Weichert W, Warth A. Harms A, et al. Among authors: weichert w. Lung Cancer. 2015 Dec;90(3):484-91. doi: 10.1016/j.lungcan.2015.10.001. Epub 2015 Oct 9. Lung Cancer. 2015. PMID: 26490121 Review.

78

Mutations in genes encoding PI3K-AKT and MAPK signaling define anogenital papillary hidradenoma.

Pfarr N, Sinn HP, Klauschen F, Flechtenmacher C, Bockmayr M, Ridinger K, von Winterfeld M, Warth A, Lorenz K, Budczies J, Penzel R, Lennerz JK, Endris V, Weichert W, Stenzinger A. Pfarr N, et al. Among authors: weichert w. Genes Chromosomes Cancer. 2016 Feb;55(2):113-9. doi: 10.1002/gcc.22315. Epub 2015 Oct 23. Genes Chromosomes Cancer. 2016. PMID: 26493284

79

Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases.

Warth A, Körner S, Penzel R, Muley T, Dienemann H, Schirmacher P, von Knebel-Doeberitz M, Weichert W, Kloor M. Warth A, et al. Among authors: weichert w. Virchows Arch. 2016 Mar;468(3):313-9. doi: 10.1007/s00428-015-1892-7. Epub 2015 Dec 4. Virchows Arch. 2016. PMID: 26637197

80

Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies.

Jesinghaus M, Pfarr N, Kloor M, Endris V, Tavernar L, Muckenhuber A, von Knebel Doeberitz M, Penzel R, Weichert W, Stenzinger A. Jesinghaus M, et al. Among authors: weichert w. Genes Chromosomes Cancer. 2016 Mar;55(3):268-77. doi: 10.1002/gcc.22330. Epub 2015 Dec 9. Genes Chromosomes Cancer. 2016. PMID: 26650777

81

c-Met in chromophobe renal cell carcinoma.

Erlmeier F, Ivanyi P, Hartmann A, Autenrieth M, Wiedemann M, Weichert W, Steffens S. Erlmeier F, et al. Among authors: weichert w. Med Oncol. 2017 Feb;34(2):15. doi: 10.1007/s12032-016-0874-1. Epub 2016 Dec 29. Med Oncol. 2017. PMID: 28035577

82

Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, Penzel R, Endris V, Arsenic R, Hermann G, Stenzinger A, Weichert W, Pfarr N, Klöppel G. Jesinghaus M, et al. Among authors: weichert w. Mod Pathol. 2017 Apr;30(4):610-619. doi: 10.1038/modpathol.2016.220. Epub 2017 Jan 6. Mod Pathol. 2017. PMID: 28059096 Free article.

83

Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.

Affolter A, Samosny G, Heimes AS, Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A, Brenner W, Mann WJ, Brieger J. Affolter A, et al. Among authors: weichert w. Head Neck. 2017 Apr;39(4):623-632. doi: 10.1002/hed.24557. Epub 2017 Feb 21. Head Neck. 2017. PMID: 28221700

84

EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP^®).

Petersen I, Dietel M, Geilenkeuser WJ, Mireskandari M, Weichert W, Steiger K, Scheel AH, Büttner R, Schirmacher P, Warth A, Lasitschka F, Schildhaus HU, Kirchner T, Reu S, Kreipe H, Länger F, Tiemann M, Schulte C, Jöhrens K. Petersen I, et al. Among authors: weichert w. Pathol Res Pract. 2017 Dec;213(12):1530-1535. doi: 10.1016/j.prp.2017.09.021. Epub 2017 Sep 28. Pathol Res Pract. 2017. PMID: 29108919 Free article.

85

Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R, Zwiebel M, Strong A, Yen HY, Banerjee R, Louzada S, Fu B, Seidler B, Götzfried J, Schuck K, Hassan Z, Arbeiter A, Schönhuber N, Klein S, Veltkamp C, Friedrich M, Rad L, Barenboim M, Ziegenhain C, Hess J, Dovey OM, Eser S, Parekh S, Constantino-Casas F, de la Rosa J, Sierra MI, Fraga M, Mayerle J, Klöppel G, Cadiñanos J, Liu P, Vassiliou G, Weichert W, Steiger K, Enard W, Schmid RM, Yang F, Unger K, Schneider G, Varela I, Bradley A, Saur D, Rad R. Mueller S, et al. Among authors: weichert w. Nature. 2018 Feb 1;554(7690):62-68. doi: 10.1038/nature25459. Epub 2018 Jan 24. Nature. 2018. PMID: 29364867 Free PMC article.

86

Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer.

Reichert M, Bakir B, Moreira L, Pitarresi JR, Feldmann K, Simon L, Suzuki K, Maddipati R, Rhim AD, Schlitter AM, Kriegsmann M, Weichert W, Wirth M, Schuck K, Schneider G, Saur D, Reynolds AB, Klein-Szanto AJ, Pehlivanoglu B, Memis B, Adsay NV, Rustgi AK. Reichert M, et al. Among authors: weichert w. Dev Cell. 2018 Jun 18;45(6):696-711.e8. doi: 10.1016/j.devcel.2018.05.025. Dev Cell. 2018. PMID: 29920275 Free PMC article.

87

Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information.

Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M. Kriegsmann K, et al. Among authors: weichert w. Proteomics Clin Appl. 2019 Jan;13(1):e1800035. doi: 10.1002/prca.201800035. Epub 2018 Aug 21. Proteomics Clin Appl. 2019. PMID: 30035857

88

Candido JB, Maiques O, Boxberg M, Kast V, Peerani E, Tomás-Bort E, Weichert W, Sananes A, Papo N, Magdolen V, Sanz-Moreno V, Loessner D. Candido JB, et al. Among authors: weichert w. Cancers (Basel). 2021 Aug 5;13(16):3969. doi: 10.3390/cancers13163969. Cancers (Basel). 2021. PMID: 34439122 Free PMC article.

89

Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer.

Michelakos T, Kontos F, Kurokawa T, Cai L, Sadagopan A, Krijgsman D, Weichert W, Durrant LG, Kuppen PJK, R Ferrone C, Ferrone S. Michelakos T, et al. Among authors: weichert w. J Immunother Cancer. 2022 Mar;10(3):e004115. doi: 10.1136/jitc-2021-004115. J Immunother Cancer. 2022. PMID: 35277460 Free PMC article.

90

Loss of Gelsolin expression in human ovarian carcinomas.

Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K. Noske A, et al. Among authors: weichert w. Eur J Cancer. 2005 Feb;41(3):461-9. doi: 10.1016/j.ejca.2004.10.025. Eur J Cancer. 2005. PMID: 15691647

91

Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.

Denkert C, Thoma A, Niesporek S, Weichert W, Koch I, Noske A, Schicktanz H, Burkhardt M, Jung K, Dietel M, Kristiansen G. Denkert C, et al. Among authors: weichert w. Prostate. 2007 Mar 1;67(4):361-9. doi: 10.1002/pros.20467. Prostate. 2007. PMID: 17265445

92

Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl AC, Röske A, Eldin Elwali N, Dietel M, Denkert C. Faggad A, et al. Among authors: weichert w. Mod Pathol. 2009 Apr;22(4):579-88. doi: 10.1038/modpathol.2009.14. Epub 2009 Mar 6. Mod Pathol. 2009. PMID: 19270648 Free article.

93

Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer.

Stenzinger A, von Winterfeld M, Rabien A, Warth A, Kamphues C, Dietel M, Weichert W, Klauschen F, Wittschieber D. Stenzinger A, et al. Among authors: weichert w. Hum Pathol. 2012 Aug;43(8):1314-21. doi: 10.1016/j.humpath.2011.10.012. Epub 2012 Mar 6. Hum Pathol. 2012. PMID: 22397871

94

Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma.

Warth A, Muley T, Kossakowski CA, Goeppert B, Schirmacher P, Dienemann H, Weichert W. Warth A, et al. Among authors: weichert w. Am J Surg Pathol. 2015 Jun;39(6):793-801. doi: 10.1097/PAS.0000000000000409. Am J Surg Pathol. 2015. PMID: 25723114

95

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.

Niehr F, Weichert W, Stenzinger A, Budach V, Tinhofer I. Niehr F, et al. Among authors: weichert w. J Transl Med. 2015 Apr 1;13:106. doi: 10.1186/s12967-015-0456-6. J Transl Med. 2015. PMID: 25890004 Free PMC article.

96

SMARCA4-deficient Sinonasal Carcinoma.

Agaimy A, Weichert W. Agaimy A, et al. Among authors: weichert w. Head Neck Pathol. 2017 Dec;11(4):541-545. doi: 10.1007/s12105-017-0783-4. Epub 2017 Feb 7. Head Neck Pathol. 2017. PMID: 28176137 Free PMC article.

97

R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer.

Demir IE, Jäger C, Schlitter AM, Konukiewitz B, Stecher L, Schorn S, Tieftrunk E, Scheufele F, Calavrezos L, Schirren R, Esposito I, Weichert W, Friess H, Ceyhan GO. Demir IE, et al. Among authors: weichert w. Ann Surg. 2018 Dec;268(6):1058-1068. doi: 10.1097/SLA.0000000000002345. Ann Surg. 2018. PMID: 28692477

98

Immunohistochemical expression of CD44 in oral squamous cell carcinoma in relation to histomorphological parameters and clinicopathological factors.

Boxberg M, Götz C, Haidari S, Dorfner C, Jesinghaus M, Drecoll E, Boskov M, Wolff KD, Weichert W, Haller B, Kolk A. Boxberg M, et al. Among authors: weichert w. Histopathology. 2018 Oct;73(4):559-572. doi: 10.1111/his.13496. Epub 2018 Jul 23. Histopathology. 2018. PMID: 29468726

99

Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.

Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, Kirchner M, Budczies J, Heukamp LC, Leichsenring J, Allgäuer M, Kazdal D, Löffler H, Weichert W, Schirmacher P, Stenzinger A, Krämer A. Bochtler T, et al. Among authors: weichert w. Int J Cancer. 2020 Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11. Int J Cancer. 2020. PMID: 31970771 Free article.

100

Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.

Budczies J, Kazdal D, Allgäuer M, Christopoulos P, Rempel E, Pfarr N, Weichert W, Fröhling S, Thomas M, Peters S, Endris V, Schirmacher P, Stenzinger A. Budczies J, et al. Among authors: weichert w. Lung Cancer. 2020 Apr;142:114-119. doi: 10.1016/j.lungcan.2020.01.019. Epub 2020 Feb 1. Lung Cancer. 2020. PMID: 32143116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

624 results

Search Page